# CREATE Medicines has raised another $122 million from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and others.

*biotech · news · 2026-05-14 · The Boston Globe*

## Key points

- CREATE Medicines raised $122 million in Series B funding to advance its in vivo CAR-T pipeline.
- CREATE rebranded from Myeloid Therapeutics last fall and expanded into autoimmune disease research.
- CREATE's CAR-T therapies are generated directly inside patients, unlike traditional off-site engineered CAR-T.
- CREATE plans to request regulatory approval soon for its first autoimmune therapy clinical trial.
- Preclinical data shows CREATE's therapies demonstrate strong B-cell suppression relevant to autoimmune diseases.

**Companies:** CREATE Medicines, Capstan Therapeutics
**Countries:** United States

[Read the full story on The Boston Globe](https://www.bostonglobe.com/2026/05/14/business/create-myeloid-therapeutics-cart/)

---

Canonical: https://newsio.io/n/6af27ae4-28cd-4e10-b83f-e093a5cf9231/create-medicines-has-raised-another-122-million-from-newpath-partners-arch-ventu
Summarized by Newsio from The Boston Globe. https://newsio.io/how-it-works